1700112E06Rik Inhibitors encompass a range of compounds identified to modulate the activity of the protein expressed by the gene 1700112E06Rik. This protein, like many in cellular biology, plays a role in a multitude of intracellular processes. The inhibitors targeting this protein are characterized by their ability to interact specifically with its functional domains, thereby altering its activity. This interaction can occur through various mechanisms, including but not limited to competitive inhibition, where the inhibitor molecules bind to the active site of the protein, allosteric inhibition, where binding occurs at a site other than the active site leading to a change in the protein's conformation and activity, and irreversible inhibition, where the inhibitor forms a covalent bond with the protein, permanently affecting its function. The development of these inhibitors is rooted in an understanding of the protein's structure and functional mechanisms.
The process of identifying and characterizing 1700112E06Rik Inhibitors typically involves a combination of computational and experimental approaches. Initially, computational methods such as molecular docking and dynamic simulation are employed to predict the interaction between potential inhibitors and the target protein. These in silico studies are invaluable in identifying promising compounds by analyzing how well they fit into the active or allosteric sites of the protein and predicting the potential effects of these interactions on the protein's function. Following this, experimental validation is crucial. This involves synthesizing the predicted inhibitors and assessing their efficacy and specificity through a series of biochemical assays. These assays may include enzyme activity measurements, binding affinity studies using techniques like surface plasmon resonance or isothermal titration calorimetry, and cell-based assays to observe the physiological effects of inhibition. Such rigorous testing ensures that the identified compounds indeed modulate the activity of 1700112E06Rik in the desired manner. The ultimate goal in the study and development of these inhibitors is to gain a deeper understanding of the protein's role in cellular processes and how modulating its activity affects these processes.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Inhibits mTOR, a key regulator of cell growth and proliferation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A PI3K inhibitor, affecting cell growth and survival signaling pathways. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A potent, broad-spectrum inhibitor of protein kinases. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor, impacting various signaling pathways. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
Specifically inhibits p38 MAP kinase, involved in stress responses. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
An inhibitor of MEK, which acts upstream of ERK in the MAPK pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits JNK, influencing apoptosis and cellular differentiation. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
Acts on DNA methylation, affecting gene expression. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
A histone deacetylase inhibitor, affecting chromatin and gene expression. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $92.00 $204.00 | 19 | |
Inhibits the Hedgehog signaling pathway. | ||||||